

National Audit of Dementia

Memory Assessment Services Spotlight
Audit 2021

Publication date: August 2022

© Healthcare Quality Improvement Partnership Ltd. (2022)

Authors

This report was prepared by Oliver Corrado, Ruth Essel, Clementine Fitch-Bunce, Emma Garling, Chloë Hood, Dasha Nicholls, Alan Quirk, and Beth Swanson.

Content is advised and approved by all members of the Steering Group. Please see our website for full details of the <u>Steering</u> <u>Group members</u> and the <u>Project Team</u>.

Partner Organisations

Age UK
Alzheimer's Society
British Geriatrics Society (BGS)
John's Campaign
Royal College of Nursing (RCN)

Acknowledgments

We would like to thank everyone who contributed to this report. We would especially like to mention:

- The patients with dementia and their carers who completed a questionnaire for this spotlight audit
- The audit leads, champions, and clinical audit staff for their hard work organising the data collection in their memory services. (For a list of participating memory services see our website)
- The Steering Group and members of the Memory Assessment Services Spotlight Audit Working Group Party (For a full list of Working Group Party members, please <u>Appendix V</u>).

If citing this report, please reference it as: Royal College of Psychiatrists (2022) National Audit of Dementia - Memory Assessment Service Spotlight Audit 2021. London: Healthcare Quality Improvement Partnership. Available from: www.nationalauditofdementia.org.uk

The National Audit of Dementia is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP). HQIP is led by a consortium of the Academy of Medical Royal Colleges, the Royal College of Nursing, and National Voices. Its aim is to promote quality improvement in patient outcomes, and in particular, to increase the impact that clinical audit, outcome review programmes and registries have on healthcare quality in England and Wales. HQIP holds the contract to commission, manage and develop the National Clinical Audit and Patient Outcomes Programme (NCAPOP), comprising around 40 projects covering care provided to people with a wide range of medical, surgical and mental health conditions. The programme is funded by NHS England, the Welsh Government and, with some individual projects, other devolved administrations and crown dependencies. www.hqip.org.uk/national-programmes.

Who should read this report?

- Clinicians, managers and other staff who provide inpatient care to people with dementia in memory services in England and Wales
- People with dementia and their families/carers
- People involved in commissioning care –
 - NHS England, Welsh
 Government and Clinical
 Commissioning Groups
- People who regulate care including the
 - Care Quality Commission, clinical audit
 - Quality improvement professionals

SUMMARY

National Audit of Dementia

Access and waiting times, diagnosis and treatment, and post diagnostic follow up in community based memory assessment services in the context of the COVID-19 pandemic.

Countries

England and Wales.

Participation

71% Trusts (England) and 29% Health Boards (Wales) had one or more service participating.

Sampling

Patients seen for initial assessment between January and August 2021.

Previous Reporting

The 2019 national memory service audit, NHS London Clinical Networks¹.

Alignment with NHS England objectives

NHS England Dementia: Our Vision²;

- Equal access to diagnosis for everyone
- Every person diagnosed with dementia having meaningful care following their diagnosis

Audit Standards

- National Institute for Health and Care Excellence (NICE) guideline NG97:
 Dementia: assessment, management and support for people living with dementia and their carers (June 2018)³
- Memory Services National Accreditation Programme (MSNAP): Standards for Memory Services - Seventh Edition (April 2020)⁴

KEY FINDINGS

1. Overall Wait Time and COVID-19 Impact

Average waiting time from referral to diagnosis has increased to 17.7 weeks since 2019, up from 13 weeks.

See recommendation1

Over 70% of services experienced periods of closure and over 80% had staff redeployed during 2020.

See recommendation 2

2. New Ways of Working

35% of patients had an appointment via phone or video call.

45% at their usual place of residence.

3. Routine Assessments

As part of their initial assessment:

61% of patients had a discussion recorded about eyesight.

58% had a discussion recorded about hearing.

<u>See</u> <u>recommendation 3</u>

76% had a falls history discussed and recorded.

See recommendation 4

4. Guidelines for Neuroimaging

CT/MRI scans were requested for 47% of patients, with variation in requests of 0-97.4% of patients per service. This range implies that variation is at service/protocol level, rather than assessed as appropriate in each case.

5. Post diagnostic Interventions

62% of patients with a working or confirmed dementia diagnosis were offered a post diagnostic intervention (excluding signposting to another service). Range across services is from 2.9-100% patients.

See recommendation

<u>5</u>

25% of services are not offering Cognitive Stimulation Therapy.

LIST OF RECOMMENDATIONS

COVID-19 Recovery and Impact



Services should use quality improvement methods to actively monitor waiting times from referral to diagnosis, and identify problem areas and barriers to access, including demographic and other factors (e.g. care home residents), as services continue to recover from the impact of the pandemic and associated service closures and staff redeployment.

The Dementia Change Action Network website NextSteps provides information about support available to people awaiting assessment or diagnosis

See National Collaborating Centre for Mental Health <u>Dementia Care Pathway</u> which provides guidance for recording dementia care pathway benchmarks in the Mental Health Services Data Set

Commissioners/Dementia Regional Boards should work with services to review a) the pathway to assessment, diagnosis and support and b) the post diagnostic pathway,

to ensure that support is sufficiently flexible and personcentred. This should include exploring new ways of working for how and where appointments take place and engaging with service users and carers to understand their experiences and priorities.

Helpful resources include <u>Assessment and Diagnosis</u>
of <u>Dementia</u>, an e-learning course provided by
University College London; <u>Taking Memory</u>
<u>Assessment Services (MAS) into the Future</u>, a new
resource from Leeds Beckett University

Assessments



Services should ensure that assessment appointments include discussion of hearing, alcohol consumption, eyesight and falls, and identified follow up appointments/actions are carried out and documented.

Diagnosis and Treatment



Services should ensure that protocols for referral for neuroimaging are in line with the NICE guideline and recommended good practice assessed as appropriate per patient.

See Memory Service Assessments: A New Way of Working 4.6, for guidance on clinical decision making on risks and benefits prior to requesting a scan



Post Diagnosis

Commissioners/Dementia
Regional Boards should
ensure that services can
offer/have access to Cognitive
Stimulation Therapy for
patients diagnosed with mildmoderate dementia, in line
with guideline NG97.

CONTENTS

- National Audit of Dementia
- Previous Audit in Memory Service —
Audit Background
Context of the Pandemic ————————————————————————————————————
Patient and Staff Experiences Spotlight Audit Participation Demographics COVID-19 Recovery and Impact Assessment Diagnosis and Treatment Post-Diagnostic Working Age Conclusion Appendices - Appendix I - Sampling and Methodology 39 Spotlight Audit Participation 11 12 13 14 15 16 17 18 18 19 19 19 19 19 19 19 19
Spotlight Audit Participation 17 Demographics 12 COVID-19 Recovery and Impact 13 Assessment 16 Diagnosis and Treatment 18 Post-Diagnostic 23 Working Age 24 Conclusion 25 Appendices 26 - Appendix I - Sampling and Methodology 3
Demographics 12 COVID-19 Recovery and Impact 13 Assessment 16 Diagnosis and Treatment 18 Post-Diagnostic 23 Working Age 25 Conclusion 26 Appendices 27 - Appendix I - Sampling and Methodology 3
COVID-19 Recovery and Impact 13 Assessment 16 Diagnosis and Treatment 18 Post-Diagnostic 23 Working Age 25 Conclusion 26 Appendices 27 - Appendix I - Sampling and Methodology 3
Assessment 16 Diagnosis and Treatment 18 Post-Diagnostic 21 Working Age 22 Conclusion 23 Appendices 24 - Appendix I - Sampling and Methodology 3
Diagnosis and Treatment
Post-Diagnostic 2 Working Age 2 Conclusion 2 Appendices 2 - Appendix I - Sampling and Methodology 3
Working Age
Conclusion
Appendices 2 - Appendix I - Sampling and Methodology 3
- Appendix I - Sampling and Methodology 3
- Appendix II - Full Standards 3
- Appendix III - Supplementary Data 4
- Appendix IV - MAS Spotlight Audit Data Tables4
- Appendix V - Acknowledgments 8
- Appendix VI - References 8
TABLES AND FIGURES
IABLES AND I IOUKES
Table 1. Audit participation from services across England and Wales11
Table 2. Dementia Subtype
Figure 1: Service Level Overall Wait Time (median days)
Figure 2: Service Level Brain Scans Not Requested, Requested, and Performed2
Figure A: Example of analysis run on ethnicity data
Figure B: The proportion of patients offered a virtual appointment, by service
Figure C: The proportion of patients that had any of the 4 routine assessment vs no routine
assessments, by service
Figure D: The proportion of patients that had all 4 routine assessments, by service
Figure E: The proportion of patients diagnosed with dementia, by service
Figure F: The proportion of patients offered post-diagnostic interventions, excluding signposting,
by service
Figure G: Proportion of patients with a working or confirmed diagnosis that were offered post
diagnostic interventions
Figure H: Discussion of eyesight and age 4

INTRODUCTION

National Audit of Dementia

The National Audit of Dementia (NAD) is a clinical audit programme commissioned by the Healthcare Quality Improvement Partnership on behalf of NHS England and the Welsh Government. In 2019 we undertook an audit of community-based memory assessment services in England and Wales.

What is a Memory Assessment Service?

Memory assessment services (MAS, sometimes known as memory clinics) provide specialist assessments and treatment for people where there are concerns about their memory. They are specialist services run by teams including medical staff, specialist dementia nurses, psychologists, and occupational therapists. They provide advice and assessment, leading to diagnosis if the person has dementia, which is followed by prescribing approved treatment to help people to live as well as possible with their condition. Many services also offer a range of follow up support for the person and their family or can help them to access support from other providers. People are usually referred to the MAS from their GP or sometimes another healthcare provider.

Current figures estimate that there are approximately 222 memory services in England ⁵ and 25 in Wales. ⁶

Previous Audit in Memory Services

In 2013 the Royal College of Psychiatrists carried out a survey of MAS in England ⁵ which found that many aspects of service such as waiting times for assessment and diagnosis varied greatly across the country, and that patient numbers had increased fourfold between 2011 and 2013. The survey was repeated in 2014, finding that between 2013 and 2014, the number of patients seen by MAS increased by 31% on average but there was no significant increase in capacity. The average waiting time from referral to assessment increased from 5.2 weeks in 2013 to 5.4 weeks in 2014, and waiting time from assessment to diagnosis increased from 8.4 to 8.6 weeks. Differences in average waiting times between services also increased. Cognitive Stimulation Therapy (CST) and life story work were available to people with dementia in around two-thirds of memory clinics. Education and support for carers was available via almost all clinics. These figures did not increase greatly between 2013 and 2014.

In 2016 and 2019 the London Dementia Clinical Network conducted two rounds of audit for London memory services collecting data at both service and patient level. Variation was noted in neuroimaging practice, neuropsychology referrals, diagnosis subtype, non-dementia diagnoses, waiting times and post-diagnostic support. Between both audits, interventions included targeted talks at the quarterly London Dementia Network meeting, the development of scanning guidance and memory services were visited to capture pathways and discuss quality improvement work. In 2019 the London Dementia Clinical Network opened the 2019 audit to services nationally – 85 services participated from across England.

AUDIT BACKGROUND

The dataset for the NAD 2021/22 audit is closely based on the above 2019 NHS audit to provide direct comparison wherever possible. Development of the dataset was led by Laura Cook, Clinical Programme Lead for Dementia for the London Clinical Network, and a Working Party of leads from memory assessment services.

See Appendix I for the audit sampling and methodology

CONTEXT OF THE PANDEMIC

This audit was originally due to commence in 2020. However, the onset of the pandemic led to suspension of these plans. Many services experienced periods of closure and were unable to see newly referred patients. Staff were redeployed or unavailable due to COVID-19. People with memory problems and dementia were often unable to access or attend face to face appointments. MAS had to adopt alternative ways of seeing patients for assessment and diagnosis. These included holding virtual appointments via phone or video calls. Principles for these and the challenges presented to services are set out in Memory Service Assessments: A New Way of Working. ⁷

The document explains that after an initial drop in GP referrals at the start of the pandemic, the number of people seeking a memory assessment was expected to rise again, and by the summer of 2020 this could already be seen (NHS Digital QOFB figures, presented by Dr Amanda Thomsell, 9 October 2020)⁸. At this point MAS were working to schedule appointments which had been held up for some weeks or months, accommodate new referrals and adapt to new ways of working, while still experiencing ongoing effects of closure and redeployment. Under these conditions it was inevitable that there would be an impact on the average time it takes for someone to be seen after referral and to receive their diagnosis. Feedback received via NHS England Cymru from services spoke of strong concern that audit results would be interpreted as meaning services were performing poorly, rather than dealing with unprecedently challenging circumstances.

The Working Party addressed this directly, adding several questions to the dataset relating to the impact of COVID-19 and provision of virtual appointments. These are presented in the <u>COVID-19 Recovery and Impact</u> section.

Audit results should be read and considered in the context of the situation created by the pandemic. Key recommendations are aimed at encouraging services to monitor waiting times and to flag up problem areas and barriers to access to Commissioners. This will ensure that the support they require during recovery and new ways of working is fully recognised.

PATIENT AND STAFF EXPERIENCES

Feedback from patients and staff sheds light on people's experience of delivering and receiving care. The following highlights some positive comments and some improvements to note from both parties.

Comments from service users are drawn from responses to a survey for patients and carers distributed by MAS during the audit.

Staff comments are from the study Memory Assessment Services in the COVID-19 Climate: An Evaluation of National Services Smith, S.J., Griffiths A., Platt, R., Robinson, O. (2021)⁹ Leeds Beckett university, with the kind permission of the authors.



STAFF MEMBERS 99

Remote Assessments

"[Remote assessments] helps to keep patient calm by being in own home. No travelling and no fears of catching Covid in a hospital setting."

"My mother has impaired hearing, so found it difficult to hear some of the conversation. The connection kept freezing, which confused my mother quite a bit."

"...I think we offered more choice to individuals, and still do... now we're thinking more about [it], actually we've got a bit more [choice]..."

"A lot of my knowledge is in doing it face to face, so we kind of restart from zero doing it in a different format. So we're still trying to find out what does this actually mean because we don't have this library of, of cases that you've seen before."

Involving Families

"Someone not having to go out and walk to hospital and also having a few members of the family present was beneficial rather than the hospital." "Yeah, but I think where it's enhanced it is where family members don't live locally. And we've been able to do, sort of, joint meetings with them whilst we've given diagnosis. Or assessments, we've been able to bring them in so they've felt more included."

Virtual Appointments

"Husband stressed because he knew phone calls were difficult for him. He was not always sure what he had heard. I could not indicate non-verbally if his answers were odd. The information was complex so hard to interpret from just voice."

"I think, you know, the advent of Microsoft Teams has enabled us to have MDT discussions that are truly multidisciplinary. And we can truly have a multidisciplinary approach towards deciding what method of assessment we're having. And it's backed up by a multitude of different professions."

Communication and Technology

"A zoom call on an ipad isn't the best way to be able to show compassion as the screen isn't big enough to pick up on facial expression. Being told you have Alzheimers by a stranger on a tv screen is quite hard to take in. Having now met the clinicians, I know they are very empathetic."

"...but people are really missing that, erm, companionship. That ability to share some of the, you know you have a complex case, and you come back and you discuss it with a couple of colleagues who help give it perspective. I think that's missing with the technology."

Access to Technology

"No internet, no mobile so had to do on landline phone, would have preferred seeing someone face to face."

"The area where we work, I think the deprivation index is higher so fewer people have fully functioning computers that they actually can use."

AUDIT PARTICIPATION

138 services across England and Wales participated in the casenote component of the audit, with a total of 5970 casenotes submitted. 134 services submitted contextual data regarding their organisations. 53 services submitted patient feedback from 251 patient/carers.


Table 1. Audit participation from services across England and Wales


Regions/ Nation	Number of NHS Mental Health Trusts/Health Boards	Participating NHS Mental Health Trusts/Health Boards	Total Participation
East of England	6	4	67%
London	10	7	70%
Midlands	14	10	71%
North East and Yorkshire	12	9	75 %
North West	8	5	63%
South East	10	8	80%
South West	8	5	63%
Wales	7	2	29%


From sampling information received (63 services only) the average number of patients seen for initial assessment in January 2021 was 36.7, ranging from 2 to 74. As a proportion of total eligible patients per service, samples ranged from 5-100%. See methodology for more information.

DEMOGRAPHICS

*figures are rounded to the nearest percentage and may not add to 100%







patients with undocumented or unknown ethnicity

Compared to 6% in 2019 NHS audit.

Although analysis was conducted 10, there were

Although analysis was conducted¹⁰, there were no significant differences in ethnicity in relation to the audit's key findings (see Figure A in appendix III).



85%

patients spoke English as their first language 4%

patients needed an interpreter **36%**

patients lived alone

COVID-19 RECOVERY AND IMPACT

services were either closed or had staff redeployed



Service Closure and Redeployment



services
had staff
redeployed
during the
first
national

66% of services experienced both closure and redeployment

72% services were closed or paused

2021: 17.7 weeks

2019: 13 weeks

Mean wait time between referral to diagnosis increased by 4.7 weeks






0 to 104 weeks

Overall Wait Time

Place of Assessment

35%

patients received a virtual initial assessment




See
recommendations
1 and 2 regarding
overall wait times
and service
provisions

NAD Memory Assessment Services Spotlight Audit 2021 | 13

COVID-19 RECOVERY AND IMPACT

Figure 1. Service Level Overall Wait Time (median days)



Overall Wait Time

During the first lockdown period in 2020 72% (96) of services experienced periods of closure ranging from less than a month (6.7%) to more than 6 months (3%) with 62% closed for between 1 and 6 months. 83% (111) of services had staff redeployed/unable to work due to the pandemic, with 42% having less than 10% staff affected and 5.2% having all staff redeployed. 66% (88) of services were affected by both closure and redeployment.

This inevitably had an effect on the average time patients had to wait between their initial referral to a MAS and receiving their diagnosis. The average overall wait time increased by 36% to 17.7 weeks.

Per service the median wait time in days ranged from 16.5 to 285 days.

Virtual Appointments

Some services found that their premises were too small to implement social distancing for the safety of patients and staff or otherwise unsuitable during the pandemic. Many services adapted to offer appointments in different ways, via home visits or via video or phone call. Just over a third of patients, (35%, 2067) had their appointments virtually. This ranged from 0-100% patients per service (see Figure B in appendix III).

115 services (of 134 participating) provided patients with virtual appointments (86%).

As part of the audit 115 patients and/or their carers responded to a survey asking about their experience of virtual appointments and 72% (80) rated this excellent or good. Benefits perceived included not having to travel/leave home, reduced appointment wait time, and being able to carry out the appointment safely whilst isolating. 94 respondents reported challenges including barriers due to visual or hearing impairment, difficulties in using the technology, and the person being assessed presenting differently on the phone as opposed to face to face.

ASSESSMENTS

patients had at least one in-clinic routine assessment:

patients had all 4 in-clinic routine assessments:

patients had their falls history recorded

71%
in 2019 NHS aud

61%

patients had discussions around eyesight/vision, the same percentage as the 2019 NHS audit



78% patients discussed their alcohol consumption

50% in 2019 NHS audit

9:

patients
discussed their
hearing,
including the use
of hearing aids

57% in 2019 NHS audit

See recommendation 3 regarding inclinic routine assessments



20%

patients were referred to occupational therapy or a diagnostic neuropsychological assessment



ASSESSMENT

Routine in-clinic assessments audited include alcohol consumption, vision and hearing loss and falls history. Onward referrals asked about were to occupational therapy and diagnostic neuropsychological assessments.

Alcohol Consumption

78.3% (4620) were asked about their alcohol consumption. 52% (3066) of patients reported consuming 0 units of alcohol per week, an increase from 50% reported in the 2019 NHS audit 8.9% (526) of patients reported consuming over 10 units of alcohol, compared with 13% in the previous audit.

Discussion of Sight and Hearing Loss

There was evidence of a discussion about eyesight and/or vision in 61.3% (3614) of patients. Routine hearing assessments, including the use of hearing aids, were documented in 58.4% (3445) of patients.

The percentage of people asked about vision and hearing was similar to those reported in the 2019 NHS audit: 61% and 57% respectively.

Falls History Taken

A falls history was taken for 76.1% (4491) of patients, compared with 71% from the 2019 NHS audit.

Referral to occupational therapy and diagnostic neuro-psychological assessments

Overall, 12.6% (744) of patients were referred to occupational therapy for a functional assessment, and 9.7% (528) were referred for diagnostic neuropsychological assessments.

In-Clinic Routine Assessments


7% (418) of patients had no in-clinic routine assessments carried out, or it was not documented by services.


Less than half of the patient sample had all routine assessments completed at 43.1% (2545). This ranged across services from 0 - 100% (see Figure C and D in appendix III). This demonstrates that some services were able to carry out routine assessments for all of their patients. It is recommended that reversible causes of cognitive decline are investigated, prior to making specialist onward referrals, including hearing and eyesight checks (NG97)³.

Research has shown that individuals with hearing loss are significantly more likely to develop dementia (Alzheimer's Society, n.d.)¹¹ but that this effect can be reversed by the use of hearing aids (Bucholc et al., 2021)¹².

Therefore, it is important that during initial assessments for dementia, all in-clinic routine assessments are completed, in particular hearing and sight tests. This will ensure other causes of displayed symptoms have been ruled out, and appropriate onward referrals for further assessments are made and actions documented.

DIAGNOSIS AND TREATMENT





100%

patients were offered medication who were deemed clinically appropriate



Medication

56%

patients with dementia received medication

83% in 2019 NHS Audit

Investigations



25%

services perform ECGs routinely brain scans requested ranged between 0 - 97% across services

DIAGNOSIS AND TREATMENT

Overall, 69.8% (4170) of patients received a diagnosis of dementia. For patients aged 65 and over this was 73% (4042) and for patients under 65 this was 30% (128). 16% (973) were diagnosed with mild cognitive impairment (MCI), with 14% (827) receiving another (non-dementia) diagnosis. 10.7% were recorded as "working" diagnosis, i.e. awaiting results or other final confirmation.

Across services the percentage of patients diagnosed with dementia ranged from 10-100% with an average of 71% (see Figure E in appendix III).

Dementia Subtype

Table 2 shows the breakdown of the dementia subtype by age (under 65/65 and over) showing broadly similar results to the subtype breakdown % reported in the 2019 NHS audit.

Table 2. Dementia Subtype

*2019 NHS audit sample is 3978, with N numbers unavailable from report

	National Audit of Dementia		2019 N	IHS audit
Diagnosis Subtype	% Under 65 (N=128)	% 65 and over (N=4042)	% Under 65	% 65 and over
Alzheimer's disease	39.1 (50)	42.4 (1713)	37	46
Vascular dementia	14.1 (18)	17.2 (695)	19	17
Dementia with Lewy bodies	3.1 (4)	1.9 (76)	0	2
Frontotemp oral dementia - Primary progressive aphasia	2.3 (3)	0.3 (14)		0.7
Frontotemp oral dementia - Posterior cortical atrophy	0.8 (1)	0.2 (10)	7	0.3
Parkinson's disease dementia	3.9 (5)	2.3 (94)	2	3
Mixed dementia	10.2 (13)	27.9 (1130)	7	25
Alcohol related dementia	6.3 (8)	0.4 (17)	12	0.4
Unspecified dementia	17.2 (22)	6.6 (267)	9	6
Other dementia	3.1 (4)	0.6 (26)	7	1

Prescription

55.7% (2293) of patients diagnosed with dementia received medication, with a further 6% (247) declining, as compared to 83% of patients offered medication in the 2019 NHS audit.

Of those patients with dementia who received medication, 55.9% (1281) received donepezil, 8.3% (191) another cholinesterase inhibitor, and 35.2% (809) memantine. Less than 1% received a cholinesterase inhibitor plus memantine. This shows a significant change since the 2019 audit, where 76% of the patients who were prescribed medication were prescribed a cholinesterase inhibitor and 23% were prescribed memantine.

Memantine is normally prescribed for patients who are at a moderate to late stage of Alzheimer's disease, or added to an existing prescription of a cholinesterase inhibitor for patients with moderate to severe disease.¹³


The apparent rise in memantine prescription may therefore relate to the pandemic – the drop in referrals during lockdown is thought to be partly caused by reluctance amongst patients to access health care services, as well as delay in GP appointments, which would lead to later referrals. The effects of service reorganisation and closure on the time from referral to diagnosis is discussed earlier in this report. These factors combined may mean that patients were assessed by services at a later stage in their dementia than would have been the case in normal circumstances. However, it could also reflect a change in prescription practice.

Neuroimaging: MRI and CT Scans

38.8% (52) of services said that they could directly view brain scans, compared to 40% in the 2019 NHS audit. Only 43.3% (58) of services said that scans were reported by neuroradiologists, compared to 76% in 2019.

A CT or MRI scan was requested for 46.6% (2750) of patients, but 6.1% (358) of these not subsequently performed, most commonly because a previous scan existed (118 patients) or the patient declined (107 patients). As in the 2019 audit, there was marked variation between services in terms of scans requested.

Figure 2. Service Level Brain Scans Not Requested, Requested, and Performed (N = 5899) with middle bar showing national average respectively



In 2019 the range of patients not requiring a scan ranged from 0-92%. Figure 2 shows the breakdown of scans requested/performed/not requested, per service. Between 2.6-100% of patients did not have a scan requested. The average waiting time for a brain scan was 2 weeks from initial assessment (compared to 5 weeks in 2019). However, this average is lowered by 76 services (56.7%) who confirmed that they request CT or MRI scans carried out prior to initial assessment appointment. Guidance provided after the 2019 NHS audit points out that this may lead to unnecessary neuroimaging, and provides a detailed breakdown of the points in the decision-making process¹⁴.

Of scans performed 31.8% (761) were MRI, 69.6% (1671) CT and 1.7% both (2019 NHS audit 26% had MRI).

Specialist Investigations

76.9% of services (103) said that they could refer patients for PET scans, 88.1% (118) for DAT scans and 44% (59) for CSF scans. From the 2019 NHS audit, 87% of services could refer patients for DAT scans, 77% for PET scans and 56% for CSF examination. 2.2% of patients had a specialist investigation carried out (2019: 2%).

POST DIAGNOSTIC INTERVENTIONS

Any Post Diagnostic Intervention

84%

patients were offered any post diagnostic intervention (excluding signposting)

Occupational therapy

is the most common intervention provided (excluding signposting)

134

services offer at least one intervention

Cognitive Stimulation Therapy (CST)

75%

services offer CST across England




72%

services commissioned to provide CST

Signposting

93%

services offer signposting as a post diagnostic intervention



47% patients received signposting as intervention



See recommendation 5 regarding cognitive stimulation therapy

POST DIAGNOSTIC INTERVENTIONS

Cognitive Stimulation Therapy

24.6% (33) of services said they were unable to provide or offer Cognitive Stimulation Therapy (CST), which is the same as reported in the 2019 NHS audit. CST has shown greater and longer lasting benefits than standard treatments (Dementia UK, 2021),¹⁵ and is recommended in NICE guidance for people with mild to moderate dementia (NG97)³.

Psychoeducation Course

53.7% (72) of services said they were unable to provide carers the opportunity to complete a psychoeducation course, compared to 26% in the 2019 NHS audit. 23.7% (1396) of carers for patients assessed by MAS were offered a psychoeducation course, and of these 768 (55%) accepted.


Any Post Diagnostic Intervention

100% (134) of services provide at least one type of post diagnostic intervention, which remains the same when CST is excluded. However, if signposting is excluded, there is a small drop to 133 services (99.3%). At patient level 89.1% (5255) received any post diagnostic intervention, with 46.7% (2757) of patients receiving signposting. This minimally decreased when signposting was excluded to 83.8% (4946) of patients, ranging across services from 2.9-100% (see Figure F in appendix III).


Patients with a confirmed diagnosis were more likely to be offered any post diagnostic intervention, with 91.5% (4292) of patients with a confirmed diagnosis offered at least one type of intervention, compared to 85% (548) of patients with a working diagnosis (see Figure G in appendix III). For patients with a dementia diagnosis, 61.9% (2547) were offered any post diagnostic intervention, excluding signposting.


ASSESSMENTS FOR WORKING AGE PATIENTS


UNDER 65



65 AND OVER







55% patients discussed eyesight

00

62% patients discussed eyesight

49% patients discussed hearing



59%

patients discussed hearing

ASSESSMENTS FOR WORKING AGE PATIENTS

Place of Assessment

30.8% (140) of under 65s were assessed in a memory clinic, compared with 26% (1552) of patients 65 and over. 33.8% (154) of under 65s were assessed in their usual place of residence, compared with 41.9% (2504) of patients 65 and over. Phone assessments were undertaken for 23.3% (106) of patients under 65, compared with 21.8% of patients 65 and over. 12.1% (55) of patients under 65 had a video assessment, in comparison to 10.2% (606) of patients 65 years and over.

Hearing/Eyesight

In the under 65s, 55% (236) had their vision assessed. This compares to 61.8% (3378) in those 65 years of age and over. 208 patients out of 429 (48.5%) under the age of 65 had their hearing assessed, compared with 3237 patients (59.2%) aged 65 and over.

Falls History

65% (279) of patients under 65 had a falls history taken, which compares to 77% (4212) for those 65 and over.

Rey Point
Patients
under 65
were just as
likely to
receive a
virtual
assessment,
as patients
aged 65 and
over

CONCLUSION

This audit was commissioned as a one off spotlight audit in memory services. We are very grateful for the input and support from NHS London Dementia Clinical Networks who conducted previous audits. Again in this audit, marked variations between services are apparent with regard to key assessments, diagnostic investigations and post diagnostic support (see Appendix III). However, results should be read as within the context of the COVID-19 pandemic and the disruption and delay it caused. Services have worked hard to adapt and to provide memory assessment using new ways of working. The results and recommendations presented here are an overview of the national picture at an unprecedented time, and provide a benchmark against which progress to recovery can be measured.

Participating services will each receive a local report with a full breakdown of results to compare with the national picture. Following this, we plan webinars in the autumn to discuss the key themes arising from the audit and foster local quality improvement projects.







National Audit of Dementia
The Royal College of Psychiatrists
21 Prescot Street
London
E1 8BB

www.nationalauditofdementia.org.uk



National Audit of Dementia

Memory Assessment Services Spotlight
Audit 2021

Appendices

APPENDIX I: SAMPLING AND METHODOLOGY

Audit Development

The audit was developed in collaboration with the London Dementia Clinical Network, NHS England. The audit is based on the London Dementia Clinical Network audit, which ran as a national audit in 2019. Additional questions were created by a service led working party to capture the impact of new ways of working.



Community-based memory services in England and Wales were invited to participate.



Audit Participation

There were 3 separate parts of the audit: an organisational questionnaire, a casenote audit and patient/carer feedback questionnaire. All three audit tools are available on our <u>website</u>.

Audit Tool



Services submitted one organisational tool per service. This consisted of 15 questions for English services, and 18 for Welsh services. The tool included questions to capture the impact of the COVID-19 pandemic on services, including whether the service was closed or paused for assessments during the first national lockdown. 134 out of 138 total registered services submitted organisational data.

Sampling

The casenote audit tool was comprised of 39 questions, and services were asked to sample 50-100 patients, seen consecutively from 1st January 2021.

To reach the required sample size, services were initially able to continue sampling patients into February 2021. However, this was extended into August 2021 where services required, for data collection. Hospitals taking part in the audit submitted information from 5970 sets of casenotes (5899 when services that submitted <20 casenotes were removed from analysis).




Patient Feedback



The patient/carer feedback form was developed by Alzheimer's Society and comprises of 19 questions about the experiences of people diagnosed with dementia during the pandemic, and their experience of virtual assessments. The tool was designed to be completed by the person living with dementia, or by a family member/carer on their behalf, and services were asked to aim for 20 responses. A total of 251 responses were received.

Data Submission

Data was submitted between 7th September 2021-7th January 2022. Due to staff redeployment and COVID-19 vaccine booster programmes, this was extended to 26th January for some services.



Inter-rater Reliability

Inter-rater reliability checks were conducted by submission of 5 casenotes from two different professionals within one service. Key findings in the report were found to be reliable by external statistician, with link to the report on the website

Total N Sample

Participating services were asked to identify patients who had an initial assessment in January 2021, and were permitted to include further months as necessary to complete their sample. We asked services to tell us the total number of patients who had initial assessment in each month from which they included patients in their sample. 107 services responded to this request, but of these 44 were unable to provide full information. From the remaining 63, the average number of patients seen for initial assessment in January 2021 was 36.7, ranging from 2 to 74. As a proportion of total eligible patients per service, samples ranged from 5-100%.

APPENDIX II: FULL STANDARDS

Memory Services Spotlight Audit Standards/tool mapping

The tools for this audit were based on those developed for the 2019 NHS National Memory Services audit by NHS London. These were developed by an expert reference group comprising of primary and secondary care clinicians, memory service managers and commissioners. The group reviewed existing standards, e.g. Memory Services National Accreditation Programme (MSNAP) standards and National Institute for Health and Care Excellence (NICE) guidance. Tools were reviewed and amended for this audit by a Working Party of clinicians (see Acknowledgements).

Organisational questions		
Is the service MSNAP accredited?	N/A	
Organisation providing memory service.	N/A	
Do you have a named research champion / lead?	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/414344/pm-dementia2020.pdf Department of Health, Prime Minister's challenge on dementia 2020, accessed as above	
Do you have a named lead for young onset dementia (under 65)?	Memory Services National Accreditation Programme Standards for Memory Services - Seventh Edition MSNAP 39. There is a named lead within the service for people with young onset dementia. MSNAP 166. The service can refer on to specialist services for rare or young onset dementia and/ or complex care needs (e.g. regional/ tertiary neurology/ neuropsychiatry services, learning disability services).	
Which patients do you request ECGs for prior to commencing cholinesterase inhibitors?	MSNAP 131. Additional tests and investigations are carried out in accordance with NICE guidance, individual and clinical need, including electrocardiogram.	

	Dementia Revealed: What Primary Care Needs to Know RCGP 2014. An ECG is mainly useful in assessing heart rhythm and rate
	prior to starting an Acetylcholinesterase Inhibitor (AChEI). They are helpful because AChEIs tend to slow the heart rate and may cause syncope. Ischaemic changes and atrial fibrillation need to be noted.
Are CT and MRI scans reported by neuroradiologists?	MSNAP 130. Additional tests and investigations are carried out in accordance with NICE guidance, individual and clinical need, including: Timely access to brain imaging in the assessment of people with suspected dementia to exclude cerebral pathologies and to help establish the subtype diagnosis.
	NICE NG97 1.2.26 If the dementia subtype is uncertain and vascular dementia is suspected, use MRI. If MRI is unavailable or contraindicated, use CT.
Can you view scan images (e.g. using PACS)?	MSNAP 130. Additional tests and investigations are carried out in accordance with NICE guidance, individual and clinical need, including: timely access to brain imaging in the assessment of people with suspected dementia to exclude cerebral pathologies and to help establish the subtype diagnosis.
Is attending imaging	MSNAP 91, 95
appointments facilitated by the memory service?	RCPsych 2019, core standards for community based mental health services, 2.1, 2.2
Are you able to refer patients for PET scans?	NICE NG97 1.2.23 If the diagnosis is uncertain (see recommendation 1.2.14) and frontotemporal dementia is suspected, use either FDG-PET or perfusion SPECT
Are you able to refer patients for DAT scans?	Parkinson's disease in adults NICE guideline [NG71] Published: 19 July 2017 1.2.6, 1.2.7
Are you able to refer patients for CSF examination	NICE NG97 1.2.15 If the diagnosis is uncertain (see recommendation 1.2.14) and Alzheimer's disease is suspected, consider examining cerebrospinal fluid for total tau or total tau and phosphorylated-tau and either amyloid beta or amyloid beta 1–42 and amyloid beta 1–40.
Are you able to refer patients for SPECT scans?	

<u></u>	
Is there an opportunity for joint working with neurology?	MSNAP 37. The memory service has access to or can refer to the following professionals for advice/support during the processes of assessing and diagnosing people living with dementia: neurologist. Access to can include the speciality of the medical lead.
Is there an opportunity for joint working with neuroradiology?	MSNAP 70. The team receives training from other professionals involved in the work of the memory service, e.g. neuroradiologists, social workers.
Is there an opportunity for joint working with	MSNAP 36. The memory service has access to or can refer to the following professionals for advice/support during the processes of assessing and diagnosing people living with dementia: geriatrician. Access to can include the speciality of the medical lead. MSNAP 75. The service provides outreach, e.g. by way of joint
geriatrics?	visits/reviews, to other professionals and staff whose responsibilities include providing care and treatment of people living with dementia/ suspected dementia Guidance: E.g. GPs; residential care, nursing homes and sheltered housing; domiciliary care; day care; hospital care, including inpatient services.
Is there an opportunity for working with Parkinson's disease clinic?	NICE guideline [NG71] 1.2.2 If Parkinson's disease is suspected, refer people quickly and untreated to a specialist with expertise in the differential diagnosis of this condition. [2006, amended 2017]
Does the service provide evidence- based interventions to patients such as Cognitive Stimulation Therapy (CST) and carer support?	MSNAP 182. People living with dementia have access to a local programme of appropriate group Cognitive Stimulation Therapy (CST). MSNAP 183. People living with dementia have access to individual Cognitive Stimulation Therapy (iCST). RSPsych Core Standards for community based mental health services: 13.2, 13.3, 13.5
Do you offer a post diagnostic follow up monitoring service?	NG97 1.2.34 Memory services and equivalent hospital- and primary-care-based multidisciplinary dementia services should offer a choice of flexible access or prescheduled monitoring appointments.

NG97 1.4.1

Do you provide or offer any of the following post diagnostic service?

Offer a range of activities to promote wellbeing that are tailored to the person's preferences.

Patient level audit	
Age at referral	N/A
Gender	N/A
Sexual Orientation	N/A
Ethnicity	N/A
Is English the first language	N/A
Did the patient need an interpreter?	MSNAP 23.2.2 The service uses interpreters who are sufficiently knowledgeable and skilled to provide a full and accurate translation and/or communication support. The patient's relatives are not used in this role unless there are exceptional circumstances Guidance: Exceptional circumstances might include crisis situations where it is not possible to get an interpreter at short notice. Consider needs associated with language including learning disability, sensory impairment etc.
Does the patient live alone	N/A
Lower Super Output Area	N/A

Referral		
Referred by:	MSNAP 91. The service provides information about how to make a referral and waiting times for assessment and treatment.	
Date referral received:		
Date seen for initial assessment:	MSNAP 94. Initial contact is made with all people who are newly referred within two weeks of referral. MSNAP 95. For planned assessments, the team sends letters in advance to patients that include: - The name and designation of the professional they will see; - An explanation of the assessment process; - Information on who can accompany them; - How to contact the team if they have any queries, require support (e.g. an interpreter), need to change the appointment or have difficulty in getting there.	

Assessment	
Place of assessment?	MSNAP 22. The assessment takes place at a time and in an environment that is acceptable to all parties.
Reported alcohol consumption per week?	MSNAP 159. Patients are offered personalised healthy lifestyle advice such as advice on healthy eating, physical activity, reducing alcohol intake and access to smoking cessation services. This is documented in the care plan.
Is there evidence of a discussion about the patient's eyesight/ vision?	NICE NG97 1.8.11 Encourage people living with dementia to have eye tests every 2 years. Consider referring people who cannot organise appointments themselves. MSNAP 120. The assessment includes a check of vision, hearing, mobility and falls.

Is there evidence of a discussion about the patient's hearing?	For guidance on hearing assessments for people with suspected or diagnosed dementia, see adults with suspected dementia in the NICE guideline on hearing loss. Hearing loss in adults: assessment and management NICE guideline [NG98]Published: 21 June 2018 1.1.8 Consider referring adults with diagnosed or suspected dementia or mild cognitive impairment to an audiology service for a hearing assessment because hearing loss may be a comorbid condition. MSNAP 120. The assessment includes a check of vision, hearing, mobility and falls.	
Is there evidence the patient was referred to occupational therapy for a functional assessment?	NICE NG97 1.4.4 Consider cognitive rehabilitation or occupational therapy to support functional ability in people living with mild to moderate dementia.	
Was a falls history taken?	NICE NG97 1.8.6 For guidance on managing the risk of falling for people living with dementia (in community and inpatient settings), see the NICE guideline on falls in older people. When using this guideline take account of the additional support people living with dementia may need to participate effectively and be aware that multifactorial falls interventions may not be suitable for a person living with severe dementia MSNAP 120.1.13 The assessment includes a check of vision, hearing, mobility and falls.	

Referred to diagnostic neuropsychological assessment?	NICE NG97 1.2.11 Consider neuropsychological testing if it is unclear whether the person has cognitive impairment or whether their cognitive impairment is caused by dementia or what the correct subtype diagnosis is.
	MSNAP 123. The service has access to in-depth assessment of occupational functioning and neuropsychological assessment as required

Investigations		
Date scan requested?	N/A	
Who requested scan?	N/A	
Was a scan performed?	N/A	
Date of CT or MRI scan?	NG97 1.2.26 If the dementia subtype is uncertain and vascular dementia is suspected, use MRI. If MRI is unavailable or contraindicated, use CT.	
Were specialist investigations performed?	MSNAP 130-133 Additional tests and investigations are carried out in accordance with NICE guidance, individual and clinical need.	

Diagnosis		
Date diagnosis given:	MSNAP 96.17,48 The diagnosis is given with the locally specified target timeframe, unless any further specialist assessments or investigations are required, or other circumstances cause delay. Reasons for delay are recorded and monitored Guidance: In England, the requirement is within 6 weeks of referral. In Wales, the requirement is within 12 weeks of referral. Investigations such as blood tests and brain scans would be considered routine rather than specialist.	

Recorded diagnosis:

NICE NG97 1.1.4

Provide people living with dementia and their family members or carers (as appropriate) with information that is relevant to their circumstances and the stage of their condition.

Treatment and post diagnostic support

MSNAP 171.

Patients and carers are involved in medication reviews and are included in discussions about purpose, expected outcomes, interactions, limitations and side effects of their medications, to enable them to make informed choice and to self-manage as far as possible.

NG971.5.2

The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.5.5 and 1.5.6.

This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.

Was medication offered?

1.5.3

Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or severe Alzheimer's disease.

Treatment should be under the conditions specified in 1.5.5.

This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.

	,	
	1.5.2 The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.5.5 and 1.5.6. This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.	
Which medication was prescribed?	1.5.3 Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or severe Alzheimer's disease.	
	Treatment should be under the conditions specified in 1.5.5.	
	This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.	
	NICE NG97 1.4.2 Offer group cognitive stimulation therapy to people living with mild to moderate dementia.	
Referred for cognitive stimulation therapy (CST)	MSNAP 182. People living with dementia have access to a local programme of appropriate group Cognitive Stimulation Therapy (CST).	
	MSNAP 183. People living with dementia have access to individual Cognitive Stimulation Therapy (iCST).	
Was the patient offered a care coordination or navigation type service (either in house or referral on)?	NICE NG97 1.3.1 Provide people living with dementia with a single named health or social care professional who is responsible for coordinating their care.	

Was the carer offered a psychoeducation course (either in house or referral on) (e.g. START, CRISP)?

NICE NG97 1.11.1

Offer carers of people living with dementia a psychoeducation and skills training intervention.

NICE NG97 1.7.2

As initial and ongoing management, offer psychosocial and environmental interventions to reduce distress in people living with dementia.

MSNAP 156.

The service provides or can signpost/ refer on to services that will offer assessment and intervention for patients who develop noncognitive symptoms. Guidance: E.g. mood disorders, psychotic symptoms and behaviour that challenges.

MSNAP 178.

Patients are offered evidence based pharmacological and psychological interventions and any exceptions are documented in the case notes.
Guidance: The number, type and frequency of psychological interventions offered are informed by the evidence base.

What other interventions were provided (e.g. psychosocial support or vocational rehab support)?

MSNAP 180.

Psychosocial interventions and postdiagnostic support are available regardless of dementia subtype and age. Guidance: An audit should be carried out of the diagnoses of people offered/ participating in psychosocial interventions and support groups.

MSNAP 187.

Patients have access to interventions delivered by appropriately trained professionals, to address their emotional needs. Guidance: Please see interventions included in the British Psychological Society: A guide to psychosocial interventions in the early stages of dementia.

Was post-diagnostic counselling offered?	MSNAP 140. Patients and their carers are able to access post-diagnostic support, individually or in a group. Guidance: This might include education, treatment, support groups or one-to-one support.	
What is provided in terms of follow up monitoring?	NICE NG97 1.1.8 After diagnosis, direct people and their family members or carers (as appropriate) to relevant services for information and support (see recommendations 1.3.1 and 1.3.2 on care coordination).	
Consent taken to be contacted for research	NICE NG97 1.1.11 Tell people living with dementia (at all stages of the condition) about research studies they could participate in. MSNAP 9.2.10,11 The service ensures that all people living with dementia and their carers are asked if they would like to add their details to a research participation register, e.g. Join Dementia Research.	

Primary care correspondence		
Were READ or SNOMED codes in relation to diagnosis included in letter correspondence to GP?	1.3.4 Service providers should ensure that information (such as care and support plans and advance care and support plans) can be easily transferred between different care settings (for example home, inpatient, community and residential care). 1.3.5 Staff delivering care and support should maximise continuity and consistency of care. Ensure that relevant information is shared and recorded in the person's care and support plan.	

APPENDIX III: SUPPLEMENTARY DATA

Figure A: Example of analysis run on ethnicity data




Figure B: The proportion of patients offered a virtual appointment, by service (N= 5899)




Figure C: The proportion of patients that had any of the 4 routine assessment vs no routine assessments, by service (N= 5899)




Figure D: The proportion of patients that had all 4 routine assessments, by service (N= 5899)




Figure E: The proportion of patients diagnosed with dementia, by service (N= 5899)




Figure F: The proportion of patients offered post-diagnostic interventions, excluding signposting, by service (N= 5899)




Figure G: Proportion of patients with a working or confirmed diagnosis that were offered post diagnostic interventions





Figure H: Discussion of eyesight and age (N=5899)



APPENDIX IV - ALL DATA TABLES

Casenote Data Tables

*NHS National Memory Services Audit 2019 data is used to provide a direct comparison wherever possible

Demographics

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	Under 65	7.3% (429)	7%
	65 and Over	92.7% (5470)	93%
Q1. Age	Range	28-102	30-102
	Mean	79.7	79
	Median	81	
Q2. Sex	Male	41.6% (2453)	43%
Q2. Jex	Female	58.4% (3446)	57%
	Male	38.9% (2294)	
	Female	54.1% (3194)	New for MAS
Q3. Gender	Non-binary/Other	O% (O)	Audit 2021
	Unknown/Not documented	6.9% (411)	
	Heterosexual/Straight	61.9% (3649)	
Q4. Sexual orientation	Gay or lesbian	0.1% (6)	
	Bisexual	0.0% (1)	New for MAS
	Other sexual orientation	0.2% (9)	Audit 2021
	Unknown/Not documented	37.9% (2234)	
Q5. Ethnicity	Asian or Asian British	4.4% (262)	4%

^{**}Casenote data was removed from organisations that submitted less than 20 casenote records

	Black, African, Black British or Caribbean	2.7% (162)	2%
	Mixed or multiple ethnic groups	1.3% (76)	1%
	White	79.6% (4695)	87%
	Another ethnic group	1.2% (70)	1%
	Unknown/Not documented	10.7% (634)	6%
	Yes	85.1% (5020)	
Q6. Is English	No	6.6% (387)	New for MAS Audit 2021
the patient's first language?	The patient is Welsh speaking	0.5% (27)	
	Unknown/Not documented	7.9% (465)	
	Yes, provided by family member	1.1% (64)	4%
	Yes, provided by interpreter	2.3% (136)	4%
Q7. Did the patient need	No	93.5% (5515)	
an interpreter?	Unknown/Not documented	2.9% (170)	
	Interpreter not available/service unable to provide	0.2% (14)	
Q8. Does the patient live	Yes	37.1% (2104)	36%
alone?	No	62.9% (3563)	64%

Referral

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	GP	92.3% (5443/5899)	94%
Q10. Who was the patient	СМНТ	1.9% (115/5899)	
referred by?	Acute Hospital	3.3% (196/5899)	
	Day Hospital	1.3% (75/5899)	

		0 (0) (07/5000)
	Other	0.4% (23/5899)
	Self-referral	0.1% (6/5899)
	Social	0.1% (7/5899)
	Care/ Rehabilitation	0.2% (13/5899)
	Memory Services Recall	0.3% (19/5899)
	Unknown	0.1% (2/5899)
	Up to 1 week	4.2% (247/5899)
	1-2 weeks	8.6% (506/5899)
	2-3 weeks	9.5% (563/5899)
	3-4 weeks	9.5% (559/5899)
	4-5 weeks	8.3% (490/5899)
	5-10 weeks	28.3% (1669/5899)
	10-20 weeks	21.0% (1237/5899)
	20-30 weeks	6.9% (408/5899)
Access Time (Referral to	30-40 weeks	1.6% (92/5899)
İnitial	40-52 weeks	1.5% (90/5899)
Assessment)	More than a year (52 weeks)	0.6% (38/5899)
	Mean (Days)	65.9
	Mean (Weeks)	9.4
	Median (Days)	45.0
	Median (Weeks)	6.4
	Range (Days)	0-727
	Range (Weeks)	0-103.9
	6 Weeks or under	48.0%
	6 Weeks of under	(2831/5899) 52.0%
	More than 6 weeks	(3068/5899)
Overall Wait Time (Referral	Up to 1 week	0.9% (48/5237)
to Diagnosis)	1-2 weeks	2.2% (116/5237)
	2-3 weeks	2.8% (146/5237)
	3-4 weeks	3.4% (178/5237)
	/ F	4.1% (213/5237)
	4-5 weeks	4.170 (215/5257)
	5-10 weeks	20.2% (1057/5237)

20-30 weeks	18.8% (984/5237)	
30-40 weeks	8.1% (426/5237)	
40-52 weeks	4.9% (255/5237)	
More than a year (52 weeks)	2.1% (108/5237)	
Mean (Days)	123.6	
Mean (Weeks)	17.7	13
Median (Days)	104.0	
Median (Weeks)	14.9	
Range (Days)	0-731	
Range (Weeks)	0-104.4	3-34
6 Weeks or under	17.6% (923/5237)	26%
More than 6 weeks	82.4% (4314/5237)	74%

Assessment

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	Clinic	28.7% (1692/5899)	58%
	Patient's usual place of residence	45.1% (2658/5899)	
Q13. Place of assessment	Phone call	23.8% (1406/5899)	
	Video call	11.2% (661/5899)	
	Other	0.7% (41/5899)	
Q14. Was the video call facilitated by	Yes	74% (489/661)	
someone else? e.g. children or	No	12.3% (81/665)	New for MAS Audit 2021
spouse	Unknown/Not documented	13.8% (91/665)	
Q15. Reported alcohol consumption per week	0 units	66% (3066/5899)	50%
	1-4 units	16.6% (768/5899)	29%

	5-9 units	5.6% (260/5899)	8%
	10-14 units	4.5% (207/5899)	6%
	More than 14 units	6.9% (319/5899)	7%
	Unknown	21.7% (1279/5899)	
Was the patient asked about alcohol consumption?	Yes	78.3% (4620/5899)	73%
Q16. Is there evidence of a	The patient's eyesight/vision	61.3% (3614/5899)	61%
discussion about:	The patient's hearing	58.4% (3445/5899)	57%
Q16. If your service is in Wales, is there evidence of a discussion about:	The individuals general current physical health status and any current difficulty	100% (91/91)	New for MAS Audit 2021
Q17. Was the patient	Yes	11.8% (699/5899)	
referred to	Patient declined	0.8% (45/5899)	New for MAS
occupational therapy for a functional	No service provided	11.3% (665/5899)	Audit 2021
assessment?	No, not appropriate	76.1% (4490/5899)	
Q18. Was a falls	Yes	76.1% (4491/5899)	71%
history taken?	No	23.9% (1408/5899)	29%
	Yes	8.3% (487/5899)	11%
Q19. Was the patient	Patient declined	0.7% (41/5899)	
referred to diagnostic	No, not appropriate	80.1% (4724/5899)	
neuropsychological assessment?	No service provided/available for referral	3.3% (193/5899)	
	Not referred, reason unknown or unclear	7.7% (454/5899)	
Any routine assessments,	Patients had at least one	92.9% (5481/5899)	
including alcohol consumption, vision,	Patients had all	43.1% (2545/5899)	
hearing loss, and falls history	No	7% (418/5899)	

Investigations

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	Yes	45.2% (2665/5899)	
Q20. Was a brain scan requested by	No	53.4% (3149/5899)	
memory service?	Requested but not carried out	1.4% (85/5899)	
	GP	4.8% (128/2665)	
Q22. Who requested the scan?	Memory Service	92.4% (2462/2665)	
	Hospital	2.8% (75/2665)	
Q23. Was a scan performed?	Yes No	89.8% (2392/2665) 10.2% (273/2665)	
perrormed.	MRI	31.8% (761/2392)	26%
Q24. What scan was performed?	СТ	69.9% (1671/2392)	
	Both	1.7% (40/2392)	
	Previous scan	43.2% (118/273)	12%
Q25. Reason scan	Contraindicated	1.5% (4/273)	
was not performed:	Patient declined	39.2% (107/273)	4%
	Not required	16.1% (44/273)	15%
	Total Brain Scans Requested	46.6% (2750/5899)	
Combined Brain Scan Requested and Performed	Brain Scan Requested and Performed	40.5% (2392/5899)	
	Brain Scan Requested and Not Performed	6.1% (358/5899)	
	Brain Scan Not Requested	53.4% (3149/5899)	
Q27. Were specialised	Yes	2.2% (130/5899)	2%

investigations performed? e.g. PET/DAT/SPECT scan/CSF	No	97.8% (5769/5899)	98%
examination	PET scan	26.9% (35/130)	
Q28. What	DAT scan	37.7% (49/130)	
specialist investigations	SPECT scan	33.8% (44/130)	
were performed?	CSF	6.2% (8/130)	
	Up to 1 week	67.7% (1804/2665)	
	1-2 weeks	12.3% (327/2665)	
	2-3 weeks	4.3% (115/2665)	
	3-4 weeks	2.4% (63/2665)	
	4-5 weeks	2.3% (61/2665)	
	5-10 weeks	6.0% (161/2665)	
Assessment to Brain Scan Request Time	10-20 weeks	3.2% (85/2665)	
	20-30 weeks	1.0% (27/2665)	
	30-40 weeks	0.5% (14/2665)	
	40-52 weeks	0.3% (8/2665)	
	Mean (Days)	13.9	
	Mean (Weeks)	2.0	
	Median (Days)	1.0	
	Median (Weeks)	0.1	
	Range (Days)	0-341	
	Up to 1 week	18.3% (437/2392)	
	1-2 weeks	6.1% (146/2392)	
	2-3 weeks	6.3% (150/2392)	
	3-4 weeks	7.5% (180/2392)	
Accessorates	4-5 weeks	8.3% (199/2392)	
Assessment to Brain Scan Time	5-10 weeks	31.1% (743/2392)	
	10-20 weeks	16.7% (399/2392)	
	20-30 weeks	3.6% (87/2392)	
	30-40 weeks	1.6% (38/2392)	
	40-52 weeks	0.6% (13/2392)	
	Mean (Days)	50.2	

	Mean (Weeks)	7.2	
	Median (Days)	39.0	
	Median (Weeks)	5.6	
	Range (Days)	0-361	
	Up to 1 week	20.7% (495/2392)	
	1-2 weeks	9.8% (235/2392)	
	2-3 weeks	9.7% (231/2392)	
	3-4 weeks	9.4% (224/2392)	
	4-5 weeks	9.7% (233/2392)	
	5-10 weeks	27.6% (660/2392)	
Brain Scan Performed Wait	10-20 weeks	11.1% (264/2392)	
Time (Brain Scan	20-30 weeks	1.6% (38/2392)	
Request to Brain Scan Performed)	30-40 weeks	0.4% (9/2392)	
Scall Periorified)	40-52 weeks	0.1% (3/2392)	
	Mean (Days)	36.1	
	Mean (Weeks)	5.2	5
	Median (Days)	29.0	
	Median (Weeks)	4.1	
	Range (Days)	0-325	

Diagnosis

Question	Responses	Memory Assessment Services Spotlight Audit 2021	NHS National Memory Services Audit 2019 %	
		% (Num/Den)	Under 65	65 and Over ¹
	Alzheimer's disease	29.4% (1734/5899)	37%	46%
	Vascular dementia	12.0% (708/5899)	19%	17%
	Dementia with Lewy bodies	1.3% (79/5899)	0%	2%
	Behavioural variant frontotemporal dementia - Primary progressive aphasia	0.3% (17/5899)	7%	0.3%
	Behavioural variant frontotemporal dementia - Posterior cortical atrophy	0.2% (11/5899)		
Q29. Recorded diagnosis	Parkinson's disease dementia	1.7% (99/5899)	2%	3%
	Mixed dementia (dementia of more than one type)	19.1% (1126/5899)	7%	25%
	Alcohol related dementia included Korsakoff Syndrome	0.4% (25/5899)	12%	0.4%
	Unspecified dementia (if working diagnosis please select this option)	4.9% (287/5899)	9%	6%
	Other dementia	0.5% (29/5899)	7%	1%
	MCI	16.3% (963/5899)	22%²	52% ²

¹ NHS data provided as under 65 and 65 and over ² Of patients not diagnosed with dementia

	Subjective cognitive impairment/no illness specified Primary psychiatric diagnosis (e.g.	1.4% (81/5899)		
	depression, anxiety, schizophrenia)	1.0% (58/5899)	15%³	5%3
	Functional cognitive disorder	0.3% (20/5899)	6%³	
	Other (not dementia)	11.2% (662/5899)		12%³
Q30. Was this diagnosis:	Confirmed	89.5% (4689/5237)	New for	
	Working	10.5% (548/5237)	Audit 2021	21
	Up to 1 week	32.0% (1674/5237)		
	1-2 weeks	6.0% (314/5237)		
	2-3 weeks	4.2% (218/5237)		
	3-4 weeks	3.6% (191/5237)		
	4-5 weeks	3.4% (177/5237)		
	5-10 weeks	16.0% (836/5237)		
Diagnosis Wait	10-20 weeks	23.4% (1225/5237)		
Time (Initial	20-30 weeks	8.3% (437/5237)		
Assessment to	30-40 weeks	2.7% (142/5237)		
Diagnosis)	40-52 weeks	0.4% (23/5237)		
	Mean (Days)	57.6		
	Mean (Weeks)	8.2		
	Median (Days)	37.0		
	Median (Weeks)	5.3		
	Range (Days)	0-338		
	6 Weeks or under	52.4% (2742/5237)		
	More than 6	47.6%		
	weeks	(2495/5237)		

³ Of patients not diagnosed with dementia

Treatment and Support

Question	Responses	Memory Assessment Services Spotlight Audit 2021	NHS National Memory Services Audit 2019 %	
		% (Num/Den)	Under 65	65 and Over ⁴
Q32. Was anti-	Yes	44.1% (2308/5237)	83% 5	
dementia medication	Patient declined No, not appropriate	4.7% (247/5237) 45.7%		
prescribed?	No, contraindicated	(2395/5237) 5.5% (287/5237)		
	Donepezil	55.9% (1290/2308)		
Q33. Which medication was	Rivastigmine oral Rivastigmine	2.9% (67/2308) 4.2% (97/2308)	7 6% ⁶	
prescribed?	transdermal patch Galantamine	1.2% (28/2308)		
This refers to the initial prescription	Memantine	35.2% (813/2308)	23%	
	AChEl and Memantine	0.6% (13/2308)	1%	
	Yes, patient accepted	3.5% (203/5764)		
Q34a. Was the	Yes, patient declined	3.2% (184/5764)		
patient offered	Yes, offered	0.6% (34/5764)		
cognitive stimulation therapy	No, not appropriate	35.9% (2068/5764)		
(CST)? Face to face	No, service not available	47.1% (2713/5764)		
	No, other	9.4% (539/5764)		
	Not offered	0.4% (23/5764)		
Q34b. Was the	Yes, patient accepted	3.0% (172/5758)		
patient offered cognitive	Yes, patient declined	4.7% (273/5758)		
stimulation therapy	Yes, offered	0.7% (38/5758)		
(CST)? Virtual	No, not appropriate (e.g. advanced dementia, no	37.5% (2159/5758)		

 ⁴ NHS data provided as under 65 and 65 and over
 ⁵ Of patients diagnosed with dementia that were offered anti-dementia medication

⁶ Prescribed a cholinesterase inhibitor

	dementia,			
	language barrier)			
	No, service not	43.2%		
	available	(2490/5758)		
	NI	10.4%		
	No, other	(599/5758)		
	Not offered	0.5% (27/5758)		
	Yes, face to face	7.1% (421/5899)		
		8.2%		
Q34. Was the	Yes, virtual	(483/5899)		
patient offered	Yes, both face to	4.4%		
cognitive	face and virtual	(260/5899)		
	race and virtual	10.9%		
stimulation therapy	Offered any CST		21% ⁷	34% ⁷
(CST)?	Offered any CST	(644/5899)	21%	34%
	Yes, patient	49.7%		
	accepted	(2763/5555)		
Q35. Was the	Yes, patient	F F0/ /300/5555	77 % ⁷	80%7
patient offered a	declined	5.5% (306/5555)		
dementia advisor or	Offered/signposted	. ,		
navigation type	only	2.8% (158/5555)		
service (either in		33.8%		
house or	No, not appropriate	(1875/5555)		
referral on)?	No, service not			
referrar only.	available	5.5% (308/5555)		
	No, other	1.6% (91/5555)		
	Not offered	1.0% (54/5555)		
Q35b. If your service	Yes, patient	82.4% (75/91)		
is in Wales, was the	accepted	02.470 (73/91)		
patient offered a	Yes, patient	6.6% (6/91)		
dementia advisor or	declined	6.6% (6/91)		
navigation type	No, not appropriate	9.9% (9/91)	New for	MAS
service from			Audit 20	21
diagnosis to end of				
life (either in house	No, other	1.1% (1/91)		
or				
referral on)?				
	Voc carer accented	13.9%		
	Yes, carer accepted	(768/5534)		
Q36. Was the carer	Yes, carer declined	6.7% (369/5534)	39% ⁷	29% ⁷
offered a	Offered not know		39%	2970
psychoeducation	whether accepted/	4.7% (259/5534)		
course (either in	signposted	,		
house or referral	No, not appropriate	3.1% (174/5534)		
on)? For example:	No, patient did not	26.3%		
START, CRISP	have dementia	(1456/5534)		
programme	No, other	4.1% (225/5534)		
	No, service not	35.1%		
	available	(1945/5534)		
		(, ,		

_

⁷ Of patients diagnosed with dementia

	No, no carer or relative	3.7% (202/5534)	
	Not offered	2.5% (136/5534)	
	Advance care	5.8%	
	planning	(342/5899)	
	Animal assisted	00/ (2/5000)	
	therapy	0% (2/5899)	
	Assistive	1.9% (114/5899)	
	technology	,	
	Cognitive behaviour therapy	0.3% (16/5899)	
	Cognitive	. ,	
	rehabilitation	0.5% (30/5899)	
	Cognitive training	0.6% (36/5899)	
	Counselling and psychotherapy	0.7% (41/5899)	
	Creative arts	0.50/ (05/5000)	
	therapies	0.5% (27/5899)	
	Dementia/Memory cafes	6.5% (383/5899)	
	Family/Systemic therapy	0.1% (5/5899)	
Q37. What other	Involvement groups	1.7% (102/5899)	
interventions were provided? (either in	Life Review Therapy	0% (0/5899)	New for MAS
house or by referral	Life story work	0.9% (56/5899)	Audit 2021
onwards)	Music therapy	0.3% (19/5899)	
on variable	Peer-support	2.8% (165/5899)	
	groups	· ·	
	Occupational	5.0%	
	therapy	(293/5899)	
	Post-diagnostic	16.5%	
	counselling	(974/5899) 8.9%	
	Post-diagnostic groups	8.9% (527/5899)	
	Reminiscence	0.7% (41/5899)	
		46.7%	
	Signposting	(2757/5899)	
	Specialist	20.4%	
	information	(1206/5899)	
	Stress/Anxiety	2.6% (152/5899)	
	management Vocational		
	rehabilitation support	0.2% (10/5899)	
	Other	18.5% (1091/5899)	
	Yes	70.9% (4182/5899)	

Any Post-diagnostic Intervention Offered	No	29.1% (1718/5899)	
Any Post-diagnostic Interventions	Yes	54.0% (3187/5899)	
Offered (Excluding Signposting)	No	46.0% (2712/5899)	
Q37a_1. In addition to the above interventions, if your service is in	Interventions aligning to the all Wales pathway of standards - standard 9	91.2% (83/91)	New for MAS Audit 2021
Wales, were you able to offer:	Other socially prescribed interventions	6.6% (6/91)	
	Yes, patient consented	12.8% (756/5899)	36% ⁸
Q38. Was the patient asked about	Yes, patient declined	10.6% (626/5899)	3070
being contacted for research?	Not appropriate	14.2% (835/5899)	
researcn?	No documented discussion	62.4% (3682/5899)	
	No	0% (0/5899)	

Primary Care correspondence

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
Q39. Were READ or SNOMED codes in relation to diagnosis	Yes	41.2% (2433/5899)	
included in letter correspondence to GP?	No	58.8% (3466/5899)	

-

⁸ Of patients diagnosed with dementia

Organisational Data Tables

*NHS National Memory Services Audit 2019 data is used to provide a direct comparison wherever possible

Service Place

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
Q0_1 My	England	98.5% (132/134)	100%
service or clinic is in:	Wales	1.5% (2/134)	New for MAS Audit 2021

Service Closure/ Staff Redeployment

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
Q1. Was your memory service	Yes, less than a month	6.7% (9/134)	
closed or paused for new	Yes, 1-3 months	38.1% (51/134)	
assessments	Yes, 4-6 months	23.9% (32/134)	New for MAS Audit 2021
during the first national	Yes, more than 6 months	3% (4/134)	
lockdown (23rd March-July 2020)?	No	28.4% (38/134)	
	Less than 10%	42.5% (57/134)	
Q2. Approximately what percentage	25%	16.4% (22/134)	
of staff were unable to work during the first national lockdown?	50%	8.2% (11/134)	New for MAS
	75%	10.4% (14/134)	Audit 2021
	100%	5.2% (7/134)	
	No staff redeployed	17.2% (23/134)	

COVID-19 Impact	Any service closure	71.7% (96/134)	
	Any redeployment	82.7% (111/134)	
	Services either closed/ paused or experienced staff redeployment	88.8% (119/134)	New for MAS Audit 2021
	Services that were both closed/ paused and experienced staff redeployment	65.7% (88/134)	

Service Organisation

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
Q3. Is your service accredited with	Yes	39.6% (53/134)	49%
the Memory Services National Accreditation Programme (MSNAP)?	No	60.4% (81/134)	51%
	Mental Health Trust	90.3% (121/134)	95%
	Acute Trust	0% (0/134)	
Q4. What	Community services provider	3.7% (5/134)	
organisation provides the	Health Board (Wales only)	0.7% (1/134)	
memory service?	GP (Wales only)	0% (0/134)	
	Learning Disability service (Wales only)	0% (0/134)	
	Other	5.2% (7/134)	
Q5. Do you have a named research	Yes	82.8% (111/134)	81%
champion/lead?	No	17.2% (23/134)	19%

Q6. Do you have a named lead for young onset dementia	Yes	52.2% (50/134)	
	No	38.8% (52/134)	
(under 65)?	N/A	9% (12/134)	
Q7. Which	All patients	24.6% (33/134)	
patients do you request an ECG for prior to commencing cholinesterase	Patients where indicated e.g. with a slow pulse or cardiac condition	72.4% (97/134)	37%¹
inhibitors?	Other	3% (4/134)	
Q8. Are CT and MRI scans	Yes	43.3% (58/134)	76%
reported by neuroradiologists?	No	56.7% (76/134)	24%
Q9. Can you view scan images (e.g.	Yes	38.8% (52/134)	40%
using medical imaging technology such as PACS)?	No	61.2% (82/134)	60%
Q10. Is attending imaging	Yes	23.9% (32/134)	
appointments facilitated by the memory service?	No	76.1% (102/134)	
Q11a. Are you able to refer patients	Yes	76.9% (103/134)	77%
for: PET scans	No	23.1% (31/134)	23%
Q11b. Are you able to refer patients	Yes	88.1% (118/134)	87%
for: DAT scans	No	11.9% (16/134)	13%
Q11c. Are you able to refer patients	Yes	44% (59/134)	56%
for: CSF examination	No	56% (75/134)	44%
Q11d. Are you able	Yes	77.6% (104/134)	New for MAS
to refer patients for: SPECT scans	No	22.4% (30/134)	Audit 2021

¹ ECG was requested for all patients prior to prescribing a cholinesterase inhibitor

Q12a. Is there an opportunity for joint working with: Neurology	Yes, regular meetings (weekly/monthly)	10.4% (14/134)	
	Yes, quarterly meetings	9% (12/134)	
	Yes, adhoc advice	69.4% (93/134)	
	No	11.2% (15/134)	18%
	Yes, regular meetings (weekly/monthly)	13.4% (18/134)	
Q12b. Is there an opportunity for joint working	Yes, quarterly meetings	7.5% (10/134)	
with: Neuroradiology	Yes, adhoc advice	60.4% (81/134)	
	No	18.7% (25/134)	30%
	Yes, regular meetings (weekly/monthly)	6.7% (9/134)	
Q12c. Is there an opportunity for	Yes, quarterly meetings	6% (8/134)	
joint working with: Geriatrics	Yes, adhoc advice	74.6% (100/134)	
	No	12.7% (17/134)	20%
070 1 1	Yes, regular meetings (weekly/monthly)	3.7% (5/134)	
Q12d. Is there an opportunity for joint working	Yes, quarterly meetings	3.7% (5/134)	New for MAS
with: Parkinson's disease clinic	Yes, adhoc advice	80.6% (108/134)	Audit 2021
	No	11.9% (16/134)	
Q13. Do you offer a post diagnostic follow up monitoring service?	Yes for all patients	59% (79/134)	
	Yes, for patients prescribed medication	26.9% (36/134)	
	Yes, Other	9.7% (13/134)	
	No	4.5% (6/134)	

Questions for Services in Wales Only

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
Q14. Is there an offer of a named contact for emotional support	Yes	100% (2/2)	New for MAS
through the assessment period?	No	0% (0/2)	Audit 2021
Q15. Is there an offer of a contact for emotional support following receiving a diagnosis and over the next 48hr period?	Yes	100% (2/2)	New for MAS Audit 2021
	No	0% (0/2)	
Q16. Is there a Dementia Diagnosis Providing	Yes	0% (0/2)	New for MAS
Emotional Support Package included as part of all MAS staff induction?	No	100% (2/2)	Audit 2021
Q16_1. What proportion of MAS staff have	Completed	0% (0/2)	New for MAS
staff have completed this package?	Not completed	0% (0/2)	Audit 2021

Post Diagnostic Services

England

England			
Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	Dementia advisor or navigation type service	73.5% (97/132)	
	Psychoeducation course e.g. STAR, CRISP programme or other	45.5% (60/132)	74%
	Vocational rehabilitation support	6.8% (9/132)	New for MAS Audit 2021
	Cognitive Stimulation Therapy (CST)	75% (99/132)	75%
	Pre-diagnostic support	49.2% (65/132)	
	Advance care planning	43.9% (58/132)	
Q17. Do you	Animal-assisted therapy	5.3% (7/132)	
provide or offer	Assistive technology	43.9% (58/132)	
any of the following post diagnostic	Cognitive behaviour therapy	37.1% (49/132)	
services?	Cognitive rehabilitation	25% (33/132)	
	Cognitive training	13.6% (18/132)	
	Counselling and psychotherapy	46.2% (61/132)	New for MAS Audit 2021
	Creative arts therapies	11.4% (15/132)	
	Dementia/Memory cafes	56.8% (75/132)	
	Family/Systemic therapy	17.4% (23/132)	
	Involvement groups	23.5% (31/132)	
	Life Review Therapy	2.3% (3/132)	
	Life story work	47.7% (63/132)	
	Music therapy	23.5% (31/132)	
	Peer-support groups	37.1% (49/132)	

	Occupational therapy	76.5% (101/132)	
	Post-diagnostic counselling	66.7% (88/132)	
	Post-diagnostic groups	62.9% (83/132)	
	Reminiscence	26.5% (35/132)	
	Signposting	93.2% (123/132)	
	Specialist information	65.9% (87/132)	
	Stress/Anxiety management	49.2% (65/132)	
Q18. Are these services commissioned?	Provided a commissioned service	27.8% (27/97)	
Dementia advisor or navigation type	Yes, via another provider	62.9% (61/97)	
service	Provide but it is not commissioned	9.3% (9/97)	
Q18. Are these services commissioned?	Provided a commissioned service	56.7% (34/60)	
Psychoeducation	Yes, via another provider	18.3% (11/60)	
course e.g. STAR, CRISP	Provide but it is not commissioned	25.0% (15/60)	
Q18. Are these services commissioned?	Provided a commissioned service	11.1% (1/9)	
Vocational rehabilitation	Yes, via another provider	55.6% (5/9)	
support	Provide but it is not commissioned	33.3% (3/9)	
Q18. Are these services commissioned?	Provided a commissioned service	71.7% (71/99)	
Cognitive	Yes, via another provider	7.1% (7/99)	
Stimulation Therapy (CST)	Provide but it is not commissioned	21.2% (21/99)	
Q18. Are these services	Provided a commissioned service	63.1% (41/65)	
commissioned? Pre-diagnostic	Yes, via another provider	10.8% (7/65)	
support	Provide but it is not commissioned	26.2% (17/65)	
Q18. Are these services commissioned?	Provided a commissioned service	55.2% (32/58)	

Advance care	Yes, via another	22.4% (13/58)	
planning	provider	22.470 (15/50)	
	Provide but it is not	22.4% (13/58)	
	commissioned	22.470 (13/30)	
	Provided a		
Q18. Are these	commissioned	71.4% (5/7)	
services	service		
commissioned?	Yes, via another	20.60/ (2/7)	
Animal-assisted	provider	28.6% (2/7)	
therapy	Provide but it is not	0.00/ (0/17)	
	commissioned	0.0% (0/7)	
	Provided a		
Q18. Are these	commissioned	20.7% (12/58)	
services	service	,	
commissioned?	Yes, via another	= (70(/ (= /= 0)	
Assistive	provider	74.1% (43/58)	
technology	Provide but it is not	5 00/ /7/50\	
•	commissioned	5.2% (3/58)	
	Provided a		
Q18. Are these	commissioned	57.1% (28/49)	
services	service	(, ,	
commissioned?	Yes, via another		
Cognitive	provider	10.2% (5/49)	
behaviour therapy	Provide but it is not	70 50/ (76//0)	
	commissioned	32.7% (16/49)	
	Provided a		
Q18. Are these	commissioned	48.5% (16/33)	
services	service	, , ,	
commissioned?	Yes, via another	0.30/ /7/77)	
Cognitive	provider	9.1% (3/33)	
rehabilitation	Provide but it is not	(0 (0) (1 (77)	
	commissioned	42.4% (14/33)	
	Provided a		
010 A H	commissioned	61.1% (11/18)	
Q18. Are these	service		
services commissioned?	Yes, via another	F COV (1/10)	
	provider	5.6% (1/18)	
Cognitive training	Provide but it is not	77 70/ <i>(c/</i> 10)	
	commissioned	33.3% (6/18)	
	Provided a		
Q18. Are these	commissioned	47.5% (29/61)	
services	service		
commissioned?	Yes, via another	16.4% (10/61)	
Counselling and	provider	10.470 (10/01)	
psychotherapy	Provide but it is not	36.1% (22/61)	
	commissioned	JU.170 (ZZ/UI)	
Q18. Are these	Provided a		
services	commissioned	0% (0/15)	
commissioned?	service		
Creative arts	Yes, via another	73.3% (11/15)	
therapies	provider	75.570 (11/15)	

	Provide but it is not	26.7% (4/15)	
	commissioned	2017/0 (1/10)	
	Provided a	. , .	
Q18. Are these	commissioned	5.3% (4/75)	
services	service		
commissioned?	Yes, via another	82.7% (62/75)	
Dementia/Memory	provider	02.770 (02,70)	
cafes	Provide but it is not	12% (9/75)	
	commissioned	1270 (3770)	
	Provided a	. ,	
Q18. Are these	commissioned	60.9% (14/23)	
services	service		
commissioned?	Yes, via another	8.7% (2/23)	
Family/Systemic	provider	0.770 (2/25)	
therapy	Provide but it is not	30.4% (7/23)	
	commissioned	55.175 (1/25)	
	Provided a		
Q18. Are these	commissioned	25.8% (8/31)	
services	service		
commissioned?	Yes, via another	41.9% (13/31)	
Involvement	provider	11.570 (15/51)	
groups	Provide but it is not	32.3% (10/31)	
	commissioned	02.070 (1070.1)	
	Provided a		
Q18. Are these	commissioned	33.3% (1/3)	
services	service		
commissioned?	Yes, via another	0% (0/3)	
Life review	provider	(, ,	
therapy	Provide but it is not	66.7% (2/3)	
	commissioned	` ,	
	Provided a	(00/ (20/07)	
Q18. Are these	commissioned	46.0% (29/63)	
services	service		
commissioned?	Yes, via another provider	17.5% (11/63)	
Life story work	Provide but it is not		
	commissioned	36.5% (23/63)	
	Provided a		
	commissioned	12.9% (4/31)	
Q18. Are these	service	12.570 (47.51)	
services	Yes, via another		
commissioned?	provider	71% (22/31)	
Music therapy	Provide but it is not		
	commissioned	16.1% (5/31)	
	Provided a		
Q18. Are these	commissioned	24.5% (12/49)	
services	service	, ,	
commissioned?	Yes, via another	(1.20/./20//.0)	
Peer-support	provider	61.2% (30/49)	
groups	Provide but it is not	14.3% (7/49)	
	commissioned	14.570 (7/45)	

	D '		
Q18. Are these services	Provided a commissioned service	77.2% (78/101)	
commissioned? Occupational	Yes, via another provider	6.9% (7/101)	
therapy	Provide but it is not commissioned	15.8% (16/101)	
Q18. Are these services	Provided a commissioned service	72.7% (64/88)	
commissioned? Post-diagnostic	Yes, via another provider	11.4% (10/88)	
counselling	Provide but it is not commissioned	15.9% (14/88)	
Q18. Are these services	Provided a commissioned service	53.0% (44/83)	
commissioned? Post-diagnostic	Yes, via another provider	27.7% (23/83)	
groups	Provide but it is not commissioned	19.3% (16/83)	
Q18. Are these services	Provided a commissioned service	48.6% (17/35)	
commissioned? Reminiscence	Yes, via another provider	40% (14/35)	
Kerimiseerice	Provide but it is not commissioned	11.4% (4/35)	
Q18. Are these services	Provided a commissioned service	76.4% (94/123)	
commissioned? Signposting	Yes, via another provider	11.4% (14/123)	
Signiposting	Provide but it is not commissioned	12.2% (15/123)	
Q18. Are these services	Provided a commissioned service	85.1% (74/87)	
commissioned? Specialist	Yes, via another provider	6.9% (6/87)	
information	Provide but it is not commissioned	8.0% (7/87)	
Q18. Are these services	Provided a commissioned service	63.1% (41/65)	
commissioned? Stress/Anxiety	Yes, via another provider	6.2% (4/65)	
management	Provide but it is not commissioned	30.8% (20/65)	

Wales Post Diagnostic Services

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
Q19. Do you provide or offer any of the following post diagnostic services?	Dementia advisor or navigation type service	100% (2/2)	New for MAS Audit 2021
	Psychoeducation course e.g. STAR, CRISP programme or other	100% (2/2)	
	Vocational rehabilitation support	0% (0/2)	
	Cognitive Stimulation Therapy (CST)	100% (2/2)	
	Pre-diagnostic support	50% (1/2)	
	Advance care planning	50% (1/2)	
	Animal-assisted therapy	0% (0/2)	
	Assistive technology	0% (0/2)	
	Cognitive behaviour therapy	50% (1/2)	
	Cognitive rehabilitation	50% (1/2)	
	Cognitive training	50% (1/2)	
	Counselling and psychotherapy	0% (0/2)	
	Creative arts therapies	0% (0/2)	
	Dementia/Memory cafes	50% (1/2)	
	Family/Systemic therapy	0% (0/2)	
	Involvement groups	50% (1/2)	
	Life Review Therapy	0% (0/2)	
	Life story work	50% (1/2)	
	Music therapy	0% (0/2)	
	Peer-support groups	50% (1/2)	
	Occupational therapy	100% (2/2)	

	Post-diagnostic counselling	0% (0/2)	
	Post-diagnostic groups	50% (1/2)	
	Reminiscence	50% (1/2)	
	Signposting	100% (2/2)	
	Specialist information	100% (2/2)	
	Stress/Anxiety management	50% (1/2)	
Q20. Are these services	Provided by service directly	0% (0/2)	
commissioned? Dementia advisor	Provided jointly with GP service	0% (0/2)	New for MAS Audit 2021
or navigation type service	Yes, via a 3rd sector organisation	100% (2/2)	
Q20. Are these services	Provided by service directly	0% (0/2)	
commissioned? Psychoeducation	Provided jointly with GP service	0% (0/2)	New for MAS Audit 2021
course e.g. STAR, CRISP	Yes, via a 3rd sector organisation	100% (2/2)	
Q20. Are these services	Provided by service directly	0% (0/0)	
commissioned? Vocational	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
rehabilitation support	Yes, via a 3rd sector organisation	0% (0/0)	
Q20. Are these services	Provided by service directly	100% (2/2)	
commissioned? Cognitive	Provided jointly with GP service	0% (0/2)	New for MAS Audit 2021
Stimulation Therapy (CST)	Yes, via a 3rd sector organisation	0% (0/2)	
Q20. Are these services	Provided by service directly	100% (1/1)	
commissioned? Pre-diagnostic	Provided jointly with GP service	0% (0/1)	New for MAS Audit 2021
support	Yes, via a 3rd sector organisation	O% (O/1)	
Q20. Are these services	Provided by service directly	100% (1/1)	
commissioned? Advance care planning	Provided jointly with GP service	O% (O/1)	New for MAS Audit 2021
	Yes, via a 3rd sector organisation	0% (0/1)	
Q20. Are these services	Provided by service directly	0% (0/0)	New for MAS
commissioned?	Provided jointly with GP service	0% (0/0)	Audit 2021

Animal-assisted therapy	Yes, via a 3rd sector organisation	0% (0/0)	
Q20. Are these services commissioned?	Provided by service directly	0% (0/0)	
	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
Assistive technology	Yes, via a 3rd sector organisation	0% (0/0)	Addit 2021
Q20. Are these	Provided by service directly	100% (1/1)	
services commissioned? Cognitive	Provided jointly with GP service	0% (0/1)	New for MAS Audit 2021
behaviour therapy	Yes, via a 3rd sector organisation	0% (0/1)	
Q20. Are these services	Provided by service directly	100% (1/1)	
commissioned?	Provided jointly with GP service	O% (O/1)	New for MAS Audit 2021
rehabilitation	Yes, via a 3rd sector organisation	0% (0/1)	
Q20. Are these	Provided by service directly	0% (0/0)	
services commissioned? Cognitive training	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
	Yes, via a 3rd sector organisation	0% (0/0)	
Q20. Are these services commissioned? Counselling and psychotherapy	Provided by service directly	100% (1/1)	
	Provided jointly with GP service	0% (0/1)	New for MAS Audit 2021
	Yes, via a 3rd sector organisation	0% (0/1)	
Q20. Are these services	Provided by service directly	0% (0/0)	
commissioned? Creative arts	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
therapies	Yes, via a 3rd sector organisation	0% (0/0)	
Q20. Are these services	Provided by service directly	0% (0/1)	
commissioned? Dementia/Memory cafes	Provided jointly with GP service	0% (0/1)	New for MAS Audit 2021
	Yes, via a 3rd sector organisation	100% (1/1)	
Q20. Are these services	Provided by service directly	0% (0/0)	
commissioned? Family/Systemic	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
therapy	Yes, via a 3rd sector organisation	0% (0/0)	

	Provided by service		
Q20. Are these services	directly	100% (1/1)	
commissioned? Involvement	Provided jointly with GP service	O% (O/1)	New for MAS Audit 2021
groups	Yes, via a 3rd sector organisation	O% (O/1)	
Q20. Are these services	Provided by service directly	0% (0/0)	
commissioned?	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
therapy	Yes, via a 3rd sector organisation	0% (0/0)	
Q20. Are these	Provided by service directly	100% (1/1)	
services commissioned?	Provided jointly with GP service	O% (O/1)	New for MAS Audit 2021
Life story work	Yes, via a 3rd sector organisation	O% (O/1)	
Q20. Are these	Provided by service directly	0% (0/0)	
services commissioned?	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
Music therapy	Yes, via a 3rd sector organisation	0% (0/0)	
Q20. Are these services	Provided by service directly	O% (O/1)	
commissioned? Peer-support groups	Provided jointly with GP service	O% (O/1)	New for MAS Audit 2021
	Yes, via a 3rd sector organisation	100% (1/1)	
Q20. Are these services commissioned? Occupational	Provided by service directly	100% (2/2)	
	Provided jointly with GP service	0% (0/2)	New for MAS Audit 2021
therapy	Yes, via a 3rd sector organisation	0% (0/2)	
Q20. Are these services	Provided by service directly	0% (0/0)	NI F NAAC
commissioned? Post-diagnostic	Provided jointly with GP service	0% (0/0)	New for MAS Audit 2021
counselling	Yes, via a 3rd sector organisation	0% (0/0)	
Q20. Are these services	Provided by service directly	0% (0/1)	Nove for MAC
commissioned? Post-diagnostic	Provided jointly with GP service	0% (0/1)	New for MAS Audit 2021
groups	Yes, via a 3rd sector organisation	100% (1/1)	N 6 1110
Q20. Are these services	Provided by service directly	100% (1/1)	New for MAS Audit 2021

commissioned? Reminiscence	Provided jointly with GP service Yes, via a 3rd sector organisation	0% (0/1) 0% (0/1)	
Q20. Are these	Provided by service directly	50% (1/2)	
services commissioned?	Provided jointly with GP service	0% (0/2)	New for MAS Audit 2021
Signposting	Yes, via a 3rd sector organisation	50% (1/2)	
Q20. Are these services commissioned? Specialist information	Provided by service directly	100% (2/2)	
	Provided jointly with GP service	0% (0/2)	New for MAS Audit 2021
	Yes, via a 3rd sector organisation	0% (0/2)	
Q20. Are these services commissioned? Stress/Anxiety management	Provided by service directly	100% (1/1)	
	Provided jointly with GP service	O% (O/1)	New for MAS Audit 2021
	Yes, via a 3rd sector organisation	O% (O/1)	

England and Wales Any Post diagnostic Interventions

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
Post diagnostic interventions (England and Wales)	Any Post diagnostic Intervention	100% (134/134)	
	Any Post diagnostic Intervention (excluding signposting)	99.3% (132/134)	
	Any Post diagnostic Intervention (excluding CST)	100% (134/134)	

Patient Feedback Data Tables

*NHS National Memory Services Audit 2019 did not collect patient feedback data

Dementia Status

Dementia Status			
Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019
	I am a person living with dementia	17.2% (44/256)	
Diago tall us shout	I am a family member of someone living with dementia	69.9% (179/256)	NowforMAC
Please tell us about yourself	I am a volunteer/support worker completing for someone living with dementia	0.8% (2/256)	New for MAS Audit 2021
	Other	12.1% (31/256)	
	I just know it's dementia	7.8% (20/257)	New for MAS Audit 2021
	Alzheimer's disease	39.3% (101/257)	
	Vascular dementia	12.8% (33/257)	
	Mixed dementia	16.7% (43/257)	
What type of	Dementia with Lewy bodies	1.9% (5/257)	
What type of dementia were you or the person	Frontotemporal dementia (FTD)	0.8% (2/257)	
you support diagnosed with?	Young-onset dementia (before 65)	0.8% (2/257)	
	Posterior cortical atrophy (PCA)	0.8% (2/257)	
	Alcohol-related brain damage	0% (0/257)	
	Unspecified dementia	0.8% (2/257)	
	Not diagnosed yet	12.1% (31/257)	
	Other	6.2% (16/257)	

Location

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	North East	8.6% (3/35)	
	North West	17.1% (6/35)	
	Yorkshire and Humber	14.3% (5/35)	
Where do you live?	West Midlands	28.6% (10/35)	New for MAS
whiere do you live:	East Midlands	0% (0/35)	Audit 2021
	East of England	0% (0/35)	
	South West	8.6% (3/35)	
	South East	14.3% (5/35)	
	London	8.6% (3/35)	
If your service is in	North Wales	0% (0/0)	New for MAS Audit 2021
Wales: Where do	Mid and West Wales	0% (0/0)	
you live?	South East Wales	0% (0/0)	
	North East	4.2% (11/166)	
	North West	6.2% (16/166)	
	Yorkshire and Humber	9.7% (25/166)	
Where does the	West Midlands	17% (44/166)	New for MAS
with dementia	East Midlands	1.9% (5/166)	Audit 2021
live?	East of England	1.2% (3/166)	
	South West	3.5% (9/166)	
	South East	11.6% (30/166)	
	London	8.9% (23/166)	
Where does the person you support with dementia live?	North Wales	100% (1/1)	Now for MAC
	Mid and West Wales	0% (0/1)	New for MAS Audit 2021
	South East Wales	0% (0/1)	
Do you know the name of the memory	Yes	79.7% (204/256)	New for MAS
	N	20.70/ /52/252	Audit 2021
service you used?	No	20.3% (52/256)	

Appointments

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	Before March 2020	13% (33/253)	
When did you start going to	23 March - end July 2020	9.9% (25/253)	Now for MAS
appointments at the memory service?	Beginning August 2020 - end December 2020	11.9% (30/253)	New for MAS Audit 2021
	January 2021 onwards	65.2% (165/253)	
	Under 6 weeks	33.2% (86/259)	
Approximately how long did you wait for a diagnosis after being referred to the memory	Between 6 and 9 weeks	17% (44/259)	New for MAS Audit 2021
	Between 9 and 12 weeks	9.3% (24/259)	
	Between 12 and 15 weeks	9.3% (24/259)	
	Between 18 and 21 weeks	3.5% (9/259)	
service?	Between 21 and 24 weeks	2.7% (7/259)	
	Over 24 weeks	15.4% (40/259)	
	Not received yet	4.6% (12/259)	
Were any of your appointments at the memory service conducted by video/ computer and/or telephone?	Yes	43.6% (113/259)	
	No	53.3% (138/259)	New for MAS Audit 2021
	Don't know	3.1% (8/259)	

Video and Telephone Appointments

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
What were the	Assessment	32.7% (37/113)	N
video and/or telephone	Diagnosis	23.9% (27/113)	New for MAS Audit 2021
appointments for?	Both	43.4% (49/113)	
Did you have enough support from the memory	Yes	92% (104/113)	
the virtual appointments (for	No	3.5% (4/113)	New for MAS Audit 2021
example a phone call or written instructions)?	Don't know	4.4% (5/113)	
Is there anything that would have	Yes	13.3% (15/113)	New for MAS Audit 2021
helped you to access the	No	72.6% (82/113)	
appointment(s) more easily?	Don't know	14.2% (16/113)	
Were you given enough support (information about your condition, being told about services, therapies or other support) following your diagnosis?	Yes	79.2% (84/106)	
	No	15.1% (16/106)	New for MAS Audit 2021
	Don't know	5.7% (6/106)	
	Excellent	33.3% (37/111)	
How would you rate your experience of having a virtual	Good	38.7% (43/111)	
	Neither good nor poor	19.8% (22/111)	New for MAS
	Poor	3.6% (4/111)	Audit 2021
appointment(s)?	Extremely poor	3.6% (4/111)	
	Don't know	0.9% (1/111)	

Demographics

Question	Responses	Memory Assessment Services Spotlight Audit 2021 % (Num/Den)	NHS National Memory Services Audit 2019 %
	Male	37.2% (93/250)	
My gender is	Female	62% (155/250)	New for MAS
My gender is	Other	0.4% (1/250)	Audit 2021
	Prefer not to say	0.4% (1/250)	
	Under 45	5.2% (13/251)	
	45 to 54	10% (25/251)	New for MAS Audit 2021
	55 to 64	17.5% (44/251)	
My age group is:	65-74	21.5% (54/251)	
	75-84	31.1% (78/251)	
	85+	14.3% (36/251)	
	Prefer not to say	0.4% (1/251)	
	White/White British	88.8% (223/251)	
	Asian/Asian British	2.8% (7/251)	
What is your ethnicity?	Black/African /Caribbean /Black British	0.8% (2/251)	New for MAS Audit 2021
	Mixed ethnic group	0.8% (2/251)	
	Prefer not to say	1.2% (3/251)	
	Other	5.6% (14/251)	

APPENDIX V – ACKNOWLEDGEMENTS

We would like to thank everyone who contributed this report. We would especially like to mention:

The National Audit of Dementia Memory Assessment Services Spotlight Audit Working Group

Kielan Arblaster, Policy Officer Alzheimer's Society

Nicola Belsham, Clinical Psychologist/Clinical Lead, Birmingham and Solihull

Vicky Cartwright, Dementia Project Support Officer Mental Health Team NHS England

Allison Cook, Locality Manager, Tees Esk and Wear Valley NHS Foundation Trust

Laura Cook, Clinical Programme Lead, Dementia and EOLC Clinical Networks, NHS London

Miranda Fern, Deputy Programme Manager, Memory Services National Accreditation network (MSNAP)

Matthew Ford Huggins, Modern Matron, Tees, Esk and Wear Valley NHS Foundation Trust

Kate Jefferies, Faculty of Old Age Psychiatry

Suzanne Joels, Consultant Psychiatrist, Camden and Islington

Rebecca Hanmer, Senior Improvement Manager, Improvement Cymru

Kumar Ponnusamy, Dementia Nurse Consultant, Norfolk & Suffolk Foundation Trust (NSFT)

Darren Vella, Mental Health Clinical Network Senior QI Manager

The National Audit of Dementia Steering Group Members

Professor Peter Crome, Honorary Professor, UCL, Emeritus Professor, Keele University (Chair)

Mary Bruce, Senior Lecturer, Association for Dementia Studies, University of Worcester

James Campbell, Associate Director, Healthcare Quality Improvement Partnership

Dr Oliver Corrado, Consultant Geriatrician and Leeds Teaching Hospitals 'Dementia Champion' (NAD Clinical Lead)

Hilary Doxford, Service User Representative, Member of 3 Nations Dementia Working Group, Alzheimer's Society Ambassador

Dr Duncan Forsyth, Consultant Geriatrician, Cambridge University Hospitals/British Geriatrics Society Dawne Garrett, Professional Lead for Older People and Dementia Care, Royal College of Nursing

Nicci Gerrard, Carer Representative, John's Campaign

Dr Vicki Leah, Lecturer in Adult Nursing, University of East London

Dasha Nicholls, Audits & Research Clinical and Strategic Director, Royal College of Psychiatrists

Natalia Plejic, Project Manager, Healthcare Quality Improvement Partnership

Alan Quirk, Head of Clinical Audit and Research, Royal College of Psychiatrists

Beth Swanson, Lead Nurse, The James Cook University Hospital (Nurse Consultant to the audit)

David Truswell, Director, Dementia Alliance for Culture and Ethnicity

The National Audit of Dementia Patient and Carer Representatives

Frank Arrojo - Carer Representative Hilary Doxford – Service User Representative

Jayne Goodrick - Carer Representative

Chris Roberts - Service User Representative

Janet Seale - Carer Representative

APPENDIX VI - REFERENCES

- NHS London. The 2019 national memory service audit. March 2020 [Accessed 7 May 2022]. https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/The-2019-national-memory-service-audit.pdf
- NHS England. Dementia [online].
 https://www.england.nhs.uk/mental health/dementia/#:~:text=Our%20vision&text=It%20sets%20out%20NHS%2
 OEngland%27s,dementia%20and%20other%20neurodegenerative%20disea
 ses
- National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline [NG97] June 2018 [Accessed 7 May 2022]. https://www.nice.org.uk/guidance/ng97
- Royal College of Psychiatrists. Memory Services National Accreditation
 Programme Standards for Memory Services Seventh Edition. April 2020
 [Accessed 7 May 2022]. https://www.rcpsych.ac.uk/improving-care/ccqi/quality-networks-accreditation/memory-services-national-accreditation-programme-msnap/msnap-standards.
- Royal College of Psychiatrists. Second English National Memory Clinics Audit Report. December 2015 [Accessed 7 May 2022]. https://silo.tips/download/second-english-national-memory-clinics-audit-report
- NHS Wales. Wales National Audit Memory Clinics. August 2014.
 [Accessed 7 May 2022].
 http://www.1000livesplus.wales.nhs.uk/sitesplus/documents/1011/Wales%20
 National%20Audit%20-%20Memory%20Clinics%20Aug%202014.pdf
- 7. NHS Yorkshire and the Humber Clinical Networks. Memory Service Assessments: A New Way of Working. Second version December 2020 [Accessed 7 May 2022].

- http://www.yhscn.nhs.uk/media/PDFs/mhdn/Dementia/Covid%2019/MAS/MSA%20-
- %20A%20New%20Way%20of%20Working%20revised%20Dec%202020.pdf
 8. National Audit of Dementia. Spotlight Audit in Memory Services. Webinar presentation. https://www.rcpsych.ac.uk/improving-care/ccqi/national-clinical-audits/national-audit-of-dementia/fifth-round-of-audit
- Smith, S.J., Griffiths A., Platt, R., Robinson, O. (2021) Memory Assessment Services in the COVID-19 Climate: An Evaluation of National Services. Leeds Beckett University. Leeds. April 2021. https://www.leedsbeckett.ac.uk/research/centre-for-dementia-research/dementia-care-and-services/
- 10. Alzheimer's Research UK. Ethnic differences in dementia diagnosis in the UK. August 2018. https://www.alzheimersresearchuk.org/ethnic-differences-dementia-diagnosis-uk/
- 11. Alzheimer's Society. (n.d.). Sight and hearing loss [online]. Available at: <u>Sight</u> and hearing loss with dementia | Alzheimer's Society (alzheimers.org.uk)
- 12. Bucholc M, McClean PL, Bauermeister S, Todd S, Ding X, Ye Q, Wang D, Huang W, Maguire LP. Association of the use of hearing aids with the conversion from mild cognitive impairment to dementia and progression of dementia: A longitudinal retrospective study. Alzheimers Dement (N Y). February 2021. https://pubmed.ncbi.nlm.nih.gov/33614893/
- 13. NHS London Dementia Clinical Network. Pathway for prescribing acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine in the treatment of Alzheimer's disease, Parkinson's Disease dementia and Dementia with Lewy bodies [Accessed 7 May 2021]. <a href="https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.england.nhs.uk%2Flondon%2Fwp-content%2Fuploads%2Fsites%2F8%2F2019%2F11%2FDementia-Medication-Prescribing-Pathway-Template-V1.1.docx&wdOrigin=BROWSELINK
- 14. NHS London Dementia Clinical Network. Neuroimaging for Dementia Guidance from the London Dementia Clinical Network. August 2018.

 https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2019/09/Neuroimaging-for-dementia-diagnosis-London-Dementia-Clinical-Network.pdf

15. Dementia UK. Meaningful activities part five: Keeping the mind fit du periods of isolation. January 2021. https://www.dementiauk.org/cogni		
	<u>stimulation</u>	